Key result
Continuous heart rate monitoring over ~16 months enables personalized MVPA thresholds in youth with CF.
Why the study?
There are no agreed heart rate thresholds for defining moderate-to-vigorous physical activity in children and young people with cystic fibrosis, making it difficult to ascertain if daily activity targets are achieved.
Can continuous heart rate data from wearable activity trackers define personalized thresholds for moderate-to-vigorous physical activity in children and young people with cystic fibrosis?
Observational (n=142)
Can continuous heart rate data from wearable activity trackers define personalized thresholds for moderate-to-vigorous physical activity in children and young people with cystic fibrosis?
Continuous heart rate monitoring via wearable trackers can establish personalized, age-adjusted thresholds for moderate-to-vigorous physical activity in children with cystic fibrosis.
May support personalized MVPA thresholds via wearables in CF youth; hypothesis-generating and requires prospective validation before practice change.
BACKGROUND: Children and young people with cystic fibrosis (CYPwCF) are encouraged to do an average of 60 min of moderate-to-vigorous physical activity (MVPA) daily. However, there are no agreed heart rate (HR) thresholds for defining MVPA, so it is difficult to ascertain whether these targets are actually achieved. Wearable activity trackers enable continuous monitoring of fitness-related measures such as HR and could be used to measure duration and intensity of habitual MVPA. We aimed to define personalized and responsive MVPA thresholds from HR in CYPwCF, to determine habitual time spent in MVPA during childhood and adolescence. METHODS: Continuous daily HR data were collected from 142 CYPwCF wearing activity trackers over 16 months. Linear mixed-effects models were used to develop personalised estimates of resting heart rate (RHR), peak heart rate (PHR) and MVPA thresholds, which were defined using the American College of Sports Medicine heart rate reserve (HRR) method. RESULTS: 309,926 days of physical activity data showed that both RHR and PHR declined with age in CYPwCF, with considerable variability within and between individuals. The HRR method produced personalised MVPA thresholds for each CYPwCF based on age, which inherently accounted for individual demographic variability and personal factors such as cardiovascular fitness or disease severity. CONCLUSIONS: By accounting for within and between person variability in RHR and PHR, our novel method provides more accurate age-related personalised MVPA thresholds for CYPwCF than existing estimates. Our findings provide population-based estimates for RHR, PHR and MVPA thresholds at different ages in CYPwCF. This approach may help guide development of international standards for objective MVPA measurement in the era of remote HR and activity monitoring and facilitate accurate measurement of habitual physical activity in children and young people.
No takes yet. Share an insight, caveat, or question.
Tanriver et al. (2024) conducted an observational in Cystic fibrosis (n=142). Continuous daily heart rate monitoring via wearable activity trackers was evaluated on Personalised estimates of resting heart rate (RHR), peak heart rate (PHR) and MVPA thresholds. Continuous daily heart rate monitoring over 16 months yielded 309,926 days of data, enabling the development of personalized moderate-to-vigorous physical activity thresholds for youth with CF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: